SIRPA and neoplasm: In presence of rituximab, hSIRPα.40A augmented tumor-cell uptake (calculated using the uptake index) of Raji cells by macrophages obtained from both SIRPA homozygous (SIRPαV1/SIRPαV1 and SIRPαV2/SIRPαV2) and heterozygous (SIRPαV1/SIRPαV2) individuals (Fig. 3c).